Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota
Cordycepin exerts multi-target therapeutic effects in PH by inhibiting PASMC proliferation via the p53-CDK1/pTERT axis, modulating gut microbiota-linked immunometabolism and induces proinflammatory macrophage senescence. These findings support cordycepin as a promising candidate for PH therapies targeting the vascular, immune, and gut-lung axes.
Authors
- Naoya Yokota (ORCID: https://orcid.org/0000-0001-5117-8528)
- Mitsuhiro Machitani (ORCID: https://orcid.org/0009-0007-0783-1885)
- Katsuya Hirano (ORCID: https://orcid.org/0000-0003-0164-1283)
- Ryou Ishikawa (ORCID: https://orcid.org/0000-0001-5625-3259)
- Kaori Ishikawa (ORCID: https://orcid.org/0000-0003-2910-8018)
- Reiji Haba
- Kazufumi Nakamura
- Zhihong Sun
- Lin-Hai Kurahara
- Gaopeng Li
- Zhixin Zhao
Institutions
- Inner Mongolia Agricultural University (CN)
- Kagawa University (JP)
- National Cancer Centre Japan (JP)
- Okayama University Hospital (JP)
- Kagawa University Hospital (JP)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1016/j.biopha.2025.118923
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00